Interesting read from The Lancet July 28, 2025
- Peter Tierney
- Oct 21
- 1 min read
“There is an urgent need for more accessible, informed screening for cirrhosis in people with MASLD or MASH, as well as the development of better tools to identify patients with MASLD or MASH, who do not have cirrhosis, who could benefit from targeted liver cancer surveillance.”
iRnovate is moving into human trials with a low risk liver biopsy tool that provides high quality liver tissue samples for timely diagnosis and intervention.
Exciting news that promises to change the trajectory of liver disease!
Comments